| Online-Ressource |
Verfasst von: | Robinson, Stephen [VerfasserIn]  |
| Dreger, Peter [VerfasserIn]  |
| Caballero, D. [VerfasserIn]  |
| Corradini, P. [VerfasserIn]  |
| Geisler, C. [VerfasserIn]  |
| Ghielmini, M. [VerfasserIn]  |
| Le Gouill, S. [VerfasserIn]  |
| Kimby, E. [VerfasserIn]  |
| Rule, S. [VerfasserIn]  |
| Vitolo, U. [VerfasserIn]  |
| Dreyling, M. [VerfasserIn]  |
| Hermine, O. [VerfasserIn]  |
Titel: | The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma |
Verf.angabe: | S. Robinson, P. Dreger, D. Caballero, P. Corradini, C. Geisler, M. Ghielmini, S. Le Gouill, E. Kimby, S. Rule, U. Vitolo, M. Dreyling and O. Hermine on behalf of the European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
E-Jahr: | 2015 |
Jahr: | [2015] |
Jahr des Originals: | 2014 |
Umfang: | 10 S. |
Illustrationen: | Diagramme |
Fussnoten: | Advance online publication: 29 August 2014 ; Gesehen am 02.07.2020 |
Titel Quelle: | Enthalten in: Leukemia |
Ort Quelle: | London : Springer Nature, 1997 |
Jahr Quelle: | 2015 |
Band/Heft Quelle: | 29(2015), 2, Seite 464-473 |
ISSN Quelle: | 1476-5551 |
Abstract: | The role of both autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) in the management of mantle cell lymphoma (MCL) remains to be clarified. We conducted a consensus project using the RAND-modified Delphi consensus procedure to provide guidance on how SCT should be used in MCL. With regard to autoSCT, there was consensus in support of: autoSCT is the standard first-line consolidation therapy; induction therapy should include high-dose cytarabine and Rituximab; complete or partial remission should be achieved before autoSCT; Rituximab maintenance following autoSCT is not indicated; and omission of autoSCT in ‘low-risk’ patients is not indicated. No consensus could be reached regarding: autoSCT in the treatment of relapsed disease following non-transplant therapy; the value of positron emission tomography scanning and minimal residual disease (MRD) monitoring; in vivo purging with Rituximab; total body irradiation conditioning for autoSCT; and preemptive Rituximab after autoSCT. For alloSCT, consensus was reached in support of: alloSCT should be considered for patients relapsing after autoSCT; reduced intensity conditioning regimens should be used; allogeneic immunotherapy should be used for MRD eradication after alloSCT; and there is a lack of prognostic criteria to guide the use of alloSCT as first-line consolidation. No consensus was reached regarding the role of alloSCT for relapsed disease following non-transplant therapy. |
DOI: | doi:10.1038/leu.2014.223 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1038/leu.2014.223 |
| Volltext: https://www.nature.com/articles/leu2014223 |
| DOI: https://doi.org/10.1038/leu.2014.223 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1703212436 |
Verknüpfungen: | → Zeitschrift |
¬The¬ EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma / Robinson, Stephen [VerfasserIn]; [2015] (Online-Ressource)